ROBOTICS & AUTOMATION
Empowering Progress
Up to 25% off Essentials Robotics and Automation titles
Side Effects of Drugs Annual
- 1st Edition, Volume 45 - October 30, 2023
- Editor: Sidhartha D. Ray
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 9 3 9 6 - 5
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 9 3 9 7 - 2
Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 45, first published in 1977, presents clinicians and medical investiga… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteSide Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 45, first published in 1977, presents clinicians and medical investigators with a critical survey of new data and trends in adverse drug reactions and interactions. Topics covered include ADRs, ADEs and SEDs: A Bird’s Eye View, Lithium, Drugs of abuse, Side effects of drugs used in the treatment of Alzheimer's disease, Sedatives and hypnotics, Antipsychotic agents, Anti-epileptic Medications, Side effects of opioid analgesics and narcotic antagonists, Anti-inflammatory and antipyretic analgesics and drugs used in gout, Side effects of local anesthetics and therapeutic gases, and more.
Other sections covered include Antihistamines (H1 receptor antagonists), Drugs that act on the respiratory tract, Positive inotropic drugs and drugs used in dysrhythmias, Beta adrenergic antagonists and antianginal drugs, Drugs acting on the cerebral and peripheral circulations, Antihypertensive drugs, and much much more.
- Provides a critical yearly survey of the new data and trends regarding the side effects of drugs
- Authored and reviewed by worldwide pioneers in the clinical and practice sciences
- Presents an essential clinical guide on the side effects of drugs for practitioners and healthcare professionals alike
Pharmacologists; clinicians; pharmaceutical companies; clinical toxicologists; clinical pharmacologists and medical libraries
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Special Reviews in SEDA 45
- Table of Essays, Annuals 1–44
- Abbreviations
- ADRs and ADEs: Focus on drug-antibody conjugates, pharmacogenomics, and COVID19 vaccines
- Introduction
- Pharmacogenomic considerations
- Immunological/hypersensitivity reactions
- Vaccine-induced adverse effects
- Analysis of toxicological reactions
- Antibody-drug conjugates
- Grades of adverse drug reactions
- FDA pregnancy categories/classification of teratogenicity
- References [Clinicians are suggested to be aware of the information contained in the following literature originating from regulatory agencies; Readers are advised to follow the most up-to-date info posted on respective websites prior to advising patients]
- Conclusion
- Chapter 1 Side effects of lithium
- Abstract
- Introduction
- References
- Chapter 2 Side effects of drugs of abuse
- Abstract
- Introduction
- Prescription drugs
- Illicit drugs
- Over the counter (OTC) drugs
- Conclusion
- References
- Chapter 3 Side effects of drugs used in the treatment of Alzheimer's disease
- Abstract
- Introduction
- Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) [SEDA-42, 55–60; SEDA-43, 71–75; SEDA-44, 69–73]
- Aducanumab [SEDA-44, 73]
- Memantine [SEDA-42, 60–63; SEDA-43, 75–76; SEDA-44, 73–74]
- Conclusion
- References
- Chapter 4 Side effects of sedatives and hypnotics
- Abstract
- Benzodiazepines (Aronson, 2016) [R]; (Sobolewski, 2021) [R]; (Haghparast et al., 2020) [R]
- Remimazolam
- Benzodiazepine receptor agonists (Aronson, 2016) [R]; (Sobolewski, 2021) [R]; (Haghparast et al., 2020) [R]
- Orexin receptor antagonists (Aronson, 2016) [R]; (Sobolewski, 2021) [R]; (Haghparast et al., 2020) [R]
- Melatonin receptor agonists (Aronson, 2016) [R]; (Sobolewski, 2021) [R]; (Haghparast et al., 2020) [R]
- Multiple drugs
- References
- Chapter 5 Side effects of antipsychotic agents
- Abstract
- Introduction
- FGAS
- SGA
- Conclusion
- References
- Chapter 6 Side effects of antiseizure medications
- Abstract
- Gamma-aminobutyric acid (GABA) receptor agonists (Aronson, 2016) [R]; (Maroney & Markovic, 2022) [R]; (Maroney & Markovic, 2021) [R]; (Walker & Ray, 2020) [R]
- GABA reuptake inhibitors (Aronson, 2016) [R]; (Maroney & Markovic, 2022) [R]; (Maroney & Markovic, 2021) [R]; (Walker & Ray, 2020) [R]
- GABA transaminase inhibitors (Aronson, 2016) [R]; (Maroney & Markovic, 2022) [R]; (Maroney & Markovic, 2021) [R]; (Walker & Ray, 2020) [R]
- GABA analogues (Aronson, 2016) [R]; (Maroney & Markovic, 2022) [R]; (Maroney & Markovic, 2021) [R]; (Walker & Ray, 2020) [R]
- Sodium channel blockers (Aronson, 2016) [R]; (Maroney & Markovic, 2021) [R]; (Walker & Ray, 2020) [R]
- Glutamate blockers (Aronson, 2016) [R]; (Maroney & Markovic, 2022) [R]; (Maroney & Markovic, 2021) [R]; (Walker & Ray, 2020) [R]
- Miscellaneous other mechanisms of action (Aronson, 2016) [R]; (Maroney & Markovic, 2022) [R]; (Maroney & Markovic, 2021) [R]; (Walker & Ray, 2020) [R]
- Multiple drugs
- References
- Chapter 7 Side effects of opioid analgesics and opioid antagonists
- Abstract
- Introduction
- Opioid full agonists [see Fig. 1; SEDA-41, 97; SEDA-42, 115, SEDA-43, 123; SEDA-44, 173]
- Partial opioid agonist/antagonist combination [see Fig. 2; SEDA-41, 97; SEDA-42, 115, SEDA-43, 123; SEDA-44, 173]
- Opioid antagonists [see Fig. 2; SEDA-41, 97; SEDA-42, 115, SEDA-43, 123; SEDA-44, 173]
- References
- Chapter 8 Side effects of anti-inflammatory and antipyretic analgesics and drugs used in gout
- Abstract
- Aniline derivatives [SEDA-43, 135; SEDA-44, 185]
- Propionic acid derivatives [SEDA-43, 142; SEDA-44, 194]
- Arylalkanoic acid derivatives [SEDA-43, 140; SEDA-44, 190]
- Salicylates [SEDA-42, 136; SEDA-43, 145]
- Drugs used in the treatment of gout [SEDA-43, 146; SEDA-44, 195]
- References
- Chapter 9 Side effects of general anaesthetics and therapeutic gases
- Abstract
- Introduction
- Intravenous Agents
- A Comparison of Adverse Drug Reactions from Ciprofol and Propofol
- Ciprofol and Propofol for Anaesthesia for Elective Surgery
- Ciprofol and Propofol for Renal Transplant
- Dexmedetomidine
- Dexmedetomidine as Procedural Sedation in Preterm and Neonate Infants
- Intranasal Dexmedetomidine in Elderly Patients
- Dexmedetomidine vs. Propofol for Sedation in Critically Ill Adults
- Low-Dose Dexmedetomidine Use in Children Undergoing OGD
- Dexmedetomidine in Lower Limb Arthroplasties
- The Effects of Dexmedetomidine in Critically Ill Neonates
- Dexmedetomidine for Procedural Sedation in Children
- Dexmedetomidine vs. Propofol Sedation in Flexible Bronchoscopy
- Dexmedetomidine Combined with Propofol for ERCP Sedation in the Elderly
- Dexmedetomidine-Suspected Fever
- Acute Dexmedetomidine Poisoning
- Esketamine
- Etomidate
- Haemodynamic Consequences Using Ketamine in the Pre-Hospital Setting
- Ketamine
- Propofol
- Effect of Sevoflurane and Propofol on Left Ventricular Strain Profiles
- Haemodynamic Effects of Ketamine and Propofol in Paediatric Populations
- Propofol Infusion Syndrome in Critically Ill Patients
- Post-Operative Delirium and Use of Volatile Anaesthetics in the Elderly
- Ciprofol in Elective Gynaecological Surgery
- Inhalational vs. Intravenous Anaesthesia on Recovery Quality
- Methohexital and Propofol in Elective Cardioversion
- Emergence Delirium after General Anaesthesia
- Choice of Sedation for ASD Closure
- Inhalational Agents
- Effect of Propofol vs. Desflurane on QTc Prolongation
- Methoxyflurane
- Cerebral Venous Thrombosis with Recreational N2O Use
- Pulmonary embolus Associated N2O Use
- Left Anterior Descending Artery (LAD) Thrombosis after High-Dose N2O Use
- N2O for Analgesia in ED
- Sevoflurane
- Renal Function during Sevoflurane or TIVA Anaesthesia
- Xenon
- References
- Chapter 10 Side effects of antihistamines (H1 receptor antagonists)
- Abstract
- Azelastine [SEDA-41, 163; SEDA-43, 189]
- Bilastine [SEDA-41, 163; SEDA-43, 190–191]
- Cetirizine [SEDA-41, 164; SEDA-42, 166; SEDA-43, 191–192]
- Chlorpheniramine [SEDA-42, 166–167; SEDA-43, 192–193]
- Cinnarizine
- Cyproheptadine [SEDA-41, 164]
- Diphenhydramine [SEDA-41, 165–166; SEDA-42, 167–168; SEDA-43, 193–195]
- Flunarizine [SEDA-41, 167–168; SEDA-42, 169]
- Hydroxyzine [SEDA-41, 168]
- Loratadine
- Olopatadine [SEDA-42, 169; SEDA-43, 195]
- References
- Chapter 11 Side effects of drugs that act on the respiratory tract
- Abstract
- Inhaled glucocorticoids [SEDA-36, 241; SEDA-37, 195; SEDA-38, 153; SEDA-39, 161; SEDA-40, 217; SEDA-41, 171; SEDA-42, 171]
- Leukotriene modifiers [SEDA-36, 245; SEDA-37, 197; SEDA-38, 160; SEDA-39, 166; SEDA-40, 219; SEDA-41, 172; SEDA-42, 172; SEDA-43, 197; SEDA-44, 409]
- β2-Adrenoceptor agonists [SEDA-36, 245; SEDA-37, 197; SEDA-38, 155; SEDA-39, 163; SEDA-40, 220; SEDA-41, 173]
- Anticholinergic drugs [SEDA-36, 245; SEDA-37, 197; SEDA-38, 158; SEDA-39, 165; SEDA-40, 222; SEDA-41, 175; SEDA-42, 173; SEDA-43, 198; SEDA-44, 409]
- Anti-fibrotic therapies [SEDA-40, 224; SEDA-41, 177; SEDA-42, 175; SEDA-43, 199; SEDA-44, 409]
- Monoclonal antibodies [SEDA-38, 161; SEDA-39, 167; SEDA-40, 225; SEDA-41, 179; SEDA-42, 178; SEDA-43, 202; SEDA-44, 409]
- References
- Chapter 12 Side effects of positive inotropic drugs and drugs used in dysrhythmias
- Abstract
- Cardiac glycosides [SEDA-42, 183–193; SEDA-43, 207–209; SEDA-44, 121–122]
- Antidysrhythmic drugs
- Inotropes
- References
- Chapter 13 Side effects of β-adrenergic antagonists and antianginal drugs
- Abstract
- Introduction
- Beta-adrenoreceptor antagonists [SEDA-42, 195; SEDA-43, 219; SEDA-44, 133]
- Adverse effects associated with propranolol and other BB use for the treatment of infantile hemangioma (IH)
- Calcium channel blockers [SEDA-42, 199; SEDA-43, 225; SEDA-44, 144]
- Inhibitors of fatty acid oxidation [SEDA-42, 203; SEDA-43, 223; SEDA-44, 149]
- Late sodium inhibitor [SEDA-41, 203; SEDA-42, 20; SEDA-44, 149]
- Potassium channel activators [SEDA-41, 202; SEDA-44, 150]
- References
- Chapter 14 Side effects of drugs acting on the cerebral and peripheral circulations
- Abstract
- Drugs used in the treatment of migraines [SEDA-42, 207–208; SEDA-43, 237–239; SEDA-44, 17–19]
- Drugs used in the treatment of pulmonary arterial hypertension [SEDA-42, 208–209; SEDA-43, 239–240; SEDA-44, 19–21]
- Peripheral vasodilators [SEDA-42, 209–210; SEDA-43, 240–241; SEDA-44, 21–22]
- Peripheral vasocontrictors [SEDA-42, 210–213; SEDA-43, 241–246; SEDA-44, 22–23]
- References
- Chapter 15 Side effects of antihypertensive drugs
- Abstract
- Introduction
- Angiotensin converting enzyme inhibitors [SEDA-40, 263; SEDA-41, 219–220; SEDA-42, 215–216; SEDA 43, 249–250; SEDA 44, 112–113]
- Angiotensin receptor blockers [SEDA-40, 263–264; SEDA-41, 220–221; SEDA-42, 216–218; SEDA-43, 250–251; SEDA-44, 113–114]
- Beta blockers [SEDA-40, 264–265; SEDA-41, 221–222; SEDA-42, 218–221; SEDA-43, 251–254; SEDA-44, 114–115]
- Calcium channel blockers [SEDA-40, 265; SEDA-41, 222–223; SEDA-42, 221–223; SEDA-43, 254–256; SEDA-44, 116]
- Alpha-1 antagonists [SEDA-15, 3303; SEDA-33, 426; SEDA-35, 378; SEDA-41, 224]
- Alpha-2 agonists [SEDA-41, 224; SEDA-42, 224–225; SEDA-44, 118]
- Vasodilators [SEDA-41, 224–225; SEDA-42, 225; SEDA-44, 118–119]
- References
- Chapter 16 Side effects of diuretics
- Abstract
- Aldosterone receptor antagonists [SEDA-41, 235; SEDA-42, 227; SEDA-43, 259]
- Carbonic anhydrase inhibitors [SEDA-41, 227; SEDA-42, 229; SEDA-43, 262]
- Loop diuretics [SEDA-41, 228; SEDA-42, 232; SEDA-43, 261]
- Thiazide and thiazide-like diuretics [SEDA-42, 223; SEDA-43, 256; SEDA-44, 116]
- References
- Chapter 17 Side effects of metals and metal antagonists
- Abstract
- Introduction
- Ammonium tetrathiomolybdate (SEDA-43, 267; SEDA-44, 421)
- D-penicillamine (SEDA-40, 279; SEDA-41, 237; SEDA-42, 239; SEDA-43, 267; SEDA-44, 421)
- Polystyrene sulfonates (kayexalate or kalimate) (SEDA-43, 267; SEDA-44, 421)
- Sodium zirconium cyclosilicate (SEDA-43, 267; SEDA-44, 421)
- References
- Chapter 18 Side effects of antiseptic drugs and disinfectants with experience of the third year of COVID-19
- Abstract
- Special review: Antiseptic drugs and disinfectants during COVID-19
- Aldehydes [SEDA-39, 209; SEDA-40, 289; SEDA-41, 251; SEDA-42, 247; SEDA-43, 279; SEDA-44, 369]
- Benzalkonium compounds [SEDA-39, 212; SEDA-40, 292; SEDA-41, 253; SEDA-42, 249; SEDA-43, 281; SEDA-44, 372]
- Guanidines
- Halogens
- References
- Chapter 19 Side effects of beta-lactams and tetracyclines
- Abstract
- Carbapenems and monobactams
- Cephalosporins
- Penicillins
- Tetracyclines
- References
- Chapter 20 Side effects of miscellaneous antibacterial drugs
- Abstract
- Introduction
- Tetracyclines
- Doxycycline
- Minocycline
- Eravacycline
- Lincosamides
- Macrolides
- Fluoroquinolones
- Levofloxacin
- Moxifloxacin
- Glycopeptides
- Oxazolidinones
- Antibiotics, miscellaneous
- Nitrofurantoin
- Polymyxin B
- Trimethoprim/sulfamethoxazole
- Daptomycin
- Conclusion
- References
- Chapter 21 Side effects of antiprotozoal drugs
- Abstract
- Anti-malarials [SEDA-40, 337; SEDA-41, 293; SEDA-42, 279]
- Leishmaniasis therapies [SEDA-40, 337; SEDA-41, 293; SEDA-42, 279]
- Other anti-protozoals [SEDA-40, 337; SEDA-41, 293; SEDA-42, 279]
- References
- Chapter 22 Side effects of antifungals
- Abstract
- Allylamines
- Azoles
- Echinocandins
- Polyenes
- Triterpenoid
- References
- Chapter 23 Side effects of antiviral drugs
- Abstract
- Drugs active against cytomegalovirus (CMV)
- Drugs active against hepatitis B virus (HBV)
- Drugs active against hepatitis C virus (HCV)
- Drugs active against herpes simplex virus-1, -2 (HSV-1, HSV-2)
- Drugs active against human immunodeficiency virus (HIV): Integrase inhibitors (INSTIs)
- Drugs active against human immunodeficiency virus (HIV): Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
- Drugs active against human immunodeficiency virus (HIV): Nucleoside/-tide reverse transcriptase inhibitors (NRTIs)
- Drugs active against human immunodeficiency virus (HIV): Protease inhibitors (PIs)
- Conclusion
- References
- Further reading
- Chapter 24 Side effects of drugs used in the treatment of tuberculosis and leprosy
- Abstract
- General
- Aminoglycosides
- Bedaquiline
- Carbapenems
- Clofazimine
- Dapsone
- Delamanid
- Ethambutol
- Fluoroquinolones
- Isoniazid
- Linezolid
- Pretomanid
- Pyrazinamide
- Rifampicin (rifampin)
- Rifamycin
- Rifapentine
- References
- Chapter 25 Side effects of vaccines
- Abstract
- Viral vaccines
- Bacterial vaccines
- Cross references
- References
- Chapter 26 Side effects of antihelminthic drugs
- Abstract
- Albendazole
- Diethylcarbamazine
- Ivermectin
- Levamisole
- Moxidectin
- Praziquantel
- References
- Chapter 27 Blood and blood treatments
- Abstract
- Introduction
- Antigens
- Coagulation proteins
- Cord blood infusion
- DNA damaging agent
- Erythropoietin
- Gene therapy
- Immunoglobulins
- COVID-19
- Immunosuppressants
- Platelets
- References
- Further reading
- Chapter 28 Side effects of drugs that affect blood coagulation, fibrinolysis and hemostasis
- Abstract
- Warfarin and direct acting oral anticoagulants (DOACs) [SEDA-44, 247 SEDA-43, 393; SEDA-42, 337]
- Apixaban
- Asundexian
- Dabigatran
- Rivaroxaban
- Warfarin
- Parenteral anticoagulants
- Enoxaparin
- Unfractionated heparin
- Prothrombotic agents [SEDA-44, 255; SEDA-43, 407; SEDA-42, 350]
- TXA
- Anticoagulant reversal agents [SEDA-44, 256; SEDA-43, 408; SEDA-42, 353]
- Thrombolytic agents [SEDA-44, 257; SEDA-43, 410; SEDA-42, 354]
- Alteplase
- References
- Further reading
- Chapter 29 Side effects of gastrointestinal drugs
- Abstract
- Acid-impacting agents
- Cathartics, laxatives, and prokinetic agents
- Antiemetic agents
- Anti-inflammatory agents
- Miscellaneous GI agents
- Biologics
- References
- Chapter 30 Side effects of agents that influence corticotrophins, corticosteroids, and prostaglandins
- Abstract
- Introduction
- Corticotrophins [SEDA-36, 603; SEDA-37, 491; SEDA-38, 425; SEDA-42, 402]
- Systemic glucocorticoids [SEDA-36, 604; SEDA-37, 492; SEDA-38, 425; SEDA-42]
- Prostaglandins and analogues [SEDA-35; SEDA-36, 604; SEDA-37, 494; SEDA-38, 428; SEDA-42]
- References
- Chapter 31 Sex hormones, related compounds and hormonal contraceptives including miscellaneous hormones
- Abstract
- Introduction
- Second generation androgen receptor antagonists
- Estrogen receptor antagonists
- Gonadotropin-releasing hormone agonists
- Aromatase inhibitors
- Selective estrogen receptor modulators
- Progestins
- Estrogens
- Hormonal contraceptives
- Combined oral contraceptives
- Testosterone replacement therapy
- Anabolics, androgens, and related compounds
- Recombinant human growth hormones
- Ergot alkaloids
- Oxytocin
- References
- Chapter 32 Side effects of thyroid hormones, iodine, and iodides, and antithyroid drugs
- Abstract
- Thyroid hormones (SEDA-42, 431–433; SEDA-43, 441–446; SEDA-44, 461–464)
- Thionamides (SEDA-42, 433–439; SEDA-43, 446–448; SEDA-44, 464–466)
- Radioactive iodine (SEDA-42, 439; SEDA-43, 448; SEDA-44, 466–468)
- References
- Chapter 33 Side effects of insulin and other antihyperglycemic drugs
- Abstract
- Introduction
- Insulin [Fig. 1; SEDA-34, 685; SEDA-36, 645; SEDA-37, 521; SEDA-38, 453; SEDA-39, 439; SEDA-40, 541; SEDA-41, 498; SEDA-42, 445; SEDA-43, 451, SEDA-44, 397]
- Antihyperglycemic drugs [see also Fig. 2] [SEDA-33, 894; SEDA-34, 688; SEDA-36, 648; SEDA-37, 526; SEDA-38, 454; SEDA-39, 435; SEDA-40, 540; SEDA-41, 496; SEDA-42, 443; SEDA-43, 451, SEDA-44, 397]
- References
- Chapter 34 Side effects of anti-lipid medications
- Abstract
- HMG-CoA reductase inhibitors
- Fibric acid derivatives
- Omega-3 fatty acids
- Icosapent ethyl
- Niacin
- Ezetimibe
- Bempedoic acid
- PCSK9 inhibitors
- Alirocumab
- Inclisiran
- Bile acid sequestrants
- References
- Further reading
- Chapter 35 Side effects of drugs for metabolic bone disease
- Abstract
- Introduction [SEDA-44]
- Bisphosphonates [SEDA-44, 472]
- Burosumab [SEDA-44, 475]
- Calcitonin [SEDA-44, 475]
- Denosumab [SEDA-44, 475]
- Romosozumab [SEDA-44, 477]
- Teriparatide and abaloparatide [SEDA-44, 478]
- Conclusion
- References
- Chapter 36 Side effects of drugs used in ocular treatment
- Abstract
- Introduction
- Medications used to treat glaucoma
- Ophthalmic anti-inflammatory agents
- Anti-microbials
- Medications used to treat dry eye
- Conclusion
- References
- Chapter 37 Side effects, adverse drug reactions and adverse drug events of psychotropic, antiepileptic, antihypertensive, antidiabetic, and antibiotics in pregnancy
- Abstract
- Antidepressant drugs [see SEDA-41]
- Antipsychotics
- Antiepileptic drugs [also see SEDA-41, 510–511]
- Antihypertensive drugs [also see SEDA-41, 512–513]
- Antidiabetic drugs [also see SEDA-41, 513–515]
- Antibiotics
- References
- Further reading
- Chapter 38 Side effects of vitamins, amino acids, nutrition, and complementary and alternative medicine
- Abstract
- Vitamin A [acitretin, alitretinoin, all-trans retinoic acid (ATRA), 13-cis retinoic acid (isotretinoin), carotenoids, etretinate] [SEDA-41, 387; SEDA-43, 513; SEDA-44, 496]
- Vitamins of the B group [SEDA-41, 390; SEDA-43, 518; SEDA-44, 499]
- Vitamin C (ascorbic acid) [SEDA-41, 392; SEDA-43, 519; SEDA-44, 499]
- Vitamin D analogues [SEDA-41, 393; SEDA-43, 519; SEDA-44, 501]
- Vitamin E (tocopherol) [SEDA-41, 394; SEDA-43, 521; SEDA-44, 501]
- Vitamin K analogues [SEDA-41, 394; SEDA-43, 521; SEDA-44, 503]
- Amino acids [SEDA-41, 394; SEDA-43, 522; SEDA-44, 503]
- Enteral nutrition [SEDA-41, 396; SEDA-43, 523; SEDA-44, 503]
- Parenteral nutrition [SEDA-41, 397; SEDA-43, 523; SEDA-44, 504]
- Complementary and alternative medicine [SEDA-42, 483; SEDA-43, 493; SEDA-44, 505]
- Conclusion
- Acknowledgement
- References
- Chapter 39 Immunomodulatory drug-induced hypophysitis and other immunomodulatory adverse reactions in multiple organ systems
- Abstract
- Introduction
- Immune checkpoint inhibitors (ICIs) [see SEDA-22, 447]
- ICI-combination-induced adverse effects
- Investigational medication
- Conclusion
- References
- Chapter 40 Side effects of radiocontrast agents and radiopharmaceuticals
- Abstract
- Introduction
- Iodine-based contrast agents [SEDA-40, 579; SEDA-41, 531; SEDA-42, 459]
- Gadolinium-based contrast agents (GBCAs) [SEDA-40, 579; SEDA-41, 531; SEDA-42, 459]
- Iron-oxide contrast agents
- Radiopharmaceuticals [SEDA-40, 579; SEDA-41, 531; SEDA-42, 459]
- References
- Chapter 41 Side effects of contaminants associated with medications and drug withdrawal
- Abstract
- Contaminants associated with medications and drug withdrawal
- Medications associated with nitrosamine contamination
- Adulterated products
- Conclusion
- References
- Reviewers
- Index of Drugs
- Index of Drug-Drug Interactions
- Index of Adverse Effects and Adverse Reactions
- No. of pages: 1052
- Language: English
- Edition: 1
- Volume: 45
- Published: October 30, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443193965
- eBook ISBN: 9780443193972
SR
Sidhartha D. Ray
Sidhartha D. Ray, PhD, FACN serves as a Senior Professor of Pharmaceutical and Biomedical Sciences at The Touro College of Pharmacy at Manhattan, New York. Prior to this he served as Professor of Pharmaceutical Sciences for nearly 2 decades at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, New York, and as the founding chair of Pharmaceutical Science department at Manchester University College of Pharmacy, Indiana, USA. He has been in the health sciences academy for over 35 years mainly focusing on pharmacy teaching, research and service. Dr. Ray's research program focus on drug & chemical induced organ toxicology, mechanistic & molecular toxicology, adverse drug reaction mechanisms, side effects of a number of therapeutically relevant drugs and environmentally significant chemicals. Over the last two decades, Dr. Ray’s seminal discoveries have provided clear understandings on the dynamic role of apoptosis, necrosis and necraptosis during organotoxic reactions and have influenced the development of safety measures for a stunning variety of xenobiotics, phytochemicals and nutraceuticals. He is internationally recognized as a leader in the scientific community and was one of the front runners in exploring mechanisms of drug and chemical-induced programmed and un-programmed cell death in in-vivo models. His landmark studies on the interplay of bcl-2, bcl-xl, p53, bad and bax during acetaminophen induced cell death and its prevention by grape seed proanthocyanidin extract has earned worldwide citations. His peer recognition and acknowledged service contributions are reflected by his election into multiple international professional organizations, such as the Society of Toxicology (SOT), Society of Free Radical Biology & Medicine (SFRBM), American Society of Pharmacology & Experimental Therapeutics (ASPET), American Association of Colleges of Pharmacy (AACP) and American College of Nutrition (ACN). Dr. Ray is an Associate Editor of Encyclopedia of Toxicology (3rd Ed, Elsevier, 2014), and serves on the editorial boards of multiple prestigious international journals, including ‘Archives of Toxicology’ and ‘Oxidative Medicine & Cellular Longevity’.
Based on his contributions to teaching, service and scholarship to health sciences in general, Dr. Ray received multiple prestigious awards, inc. the American Academy of Clinical Toxicology’s national research award (1996), ‘Fellow of the American College of Nutrition’ honor in 1999, David Newton Award for Excellence in Teaching Pharmacy (2005), the Biennial Abraham Krasnoff Memorial Award for Lifetime Scholarly Achievement (2008), Arnold & Marie Schwartz College of Pharmacy & Health Science’s ‘Wall-of-Fame’ honor (2011), the Society of Toxicology’s ‘Undergraduate Educator of the Year’ national award (2013), and the Manchester University’s ‘Outstanding Scholar of the Year’ award (2014). He currently serves on the SOT-NIH–NLM’s joint Toxlearn Project, SOT Undergraduate Task Force (2007 – present), and has previously served on the SOT’s Education Committee (2007 – 2010). In his lifetime, Dr. Ray has mentored research to numerous PharmD, MS, MD and PhD students in a number of areas of toxicology and biomedical sciences, made seminal contributions to the fields of pharmacology, toxicology, free radical biology, anticancer mechanism, phytochemicals, nutraceuticals & dietary supplements, and molecular safety sciences. Dr. Ray loves to promote ‘Lifelong Learning’ strategies to his students and clearly models his beliefs day in and day out. Visit URL: www.sidhartharay.com/ for more details.
Affiliations and expertise
Senior Professor of Pharmaceutical and Biomedical Sciences, Touro College of Pharmacy, Touro University System, Manhattan, NY, USARead Side Effects of Drugs Annual on ScienceDirect